goGermline - Revolutionary Technology
goGermline is a revolutionary technology for generating gene-targeted knockout, knock-in, humanized and targeted transgenic mice. When injecting embryonic stem (ES) cells, goGermline eliminates competition with ‘host’ embryos, resulting in 100% ES cell-derived offspring. goGermline was developed and patented by Ozgene and published in collaboration with the Max Planck Research Unit for Neurogenetics. It also won the inaugural ISTT 3Rs prize.
goGermline 2.0 is a further improvement on the already efficient goGermline technology; only male embryos are injected, only male chimeras will be generated – essentially doubling the previous goGermline efficiency of chimera production by embryo injection.
- 3Rs benefit: no female chimeras are produced
- 100% male embryos vs. average of 50% males & 50% females
- 100% males from injection sessions vs. natural range of 0-90%
What are the goGermline benefits?
Ozgene is the only company that can guarantee that only ES cell-derived animals are produced at chimera breeding. All of our mouse model projects use goGermline, which has led to greater germline efficiency, shorter project timelines and improved 3Rs of animal welfare. To experience the goGermline benefits first-hand, enquire about a mouse project with us or order goGermline embryos to trial them in your facility.
- generate: only ES cell-derived mice
- eliminate: all non-ES cell-derived mice
- reduce: time to generate knockout and knock-in mice
- increase: germline efficiency, even with challenging ES cells
- reduce: animal numbers
Germline transmission is achieved faster and more efficiently with no excess mice, expediting time to first experimental cohorts, as shown in this timeline video. It’s pretty exciting. Currently, 88% of the projects using goGermline reach germline transmission in the first month; the rest are achieved in the following month. This data was presented as a goGermline poster at the ISTT2019 meeting in Kobe.